Murai Junko

Affiliation and department：
Other affiliations (1)：

Homepage URL (1)： http://slfn11.iab.keio.ac.jp/

Research field (1)： Molecular biology

Research keywords (4)： SLFN11 , oncology , DNA damage , replication stress

Research theme for competitive and other funds (8)：

2021 - 2027 複製ストレス制御機構が引き起こす生命現象の総合的理解
2023 - 2026 SLFN11の分子メカニズムから解き明かすDNA障害型抗がん剤の真の作用機序
2023 - 2026 SLFN11の分子メカニズムから解き明かすDNA障害型抗がん剤の真の作用機序
2021 - 2025 Chemo-sensitization of brain tumors by manipulation of SLFN11
2021 - 2024 Drug discovery targeting SLFN11 the enhancer of sensitivity to DNA-damaging anti-cancer agents

Show all

Papers (74)：

Hiroshi Onji, Sota Tate, Tomohisa Sakaue, Kohei Fujiwara, Shiho Nakano, Miho Kawaida, Nobuyuki Onishi, Takashi Matsumoto, Wataru Yamagami, Takashi Sugiyama, et al. Schlafen 11 further sensitizes BRCA-deficient cells to PARP inhibitors through single-strand DNA gap accumulation behind replication forks. Oncogene. 2024. 43. 32. 2475-2489
Kohei Fujiwara, Masashi Maekawa, Yuki Iimori, Akane Ogawa, Takeshi Urano, Nobuaki Kono, Hiroyuki Takeda, Shigeki Higashiyama, Makoto Arita, Junko Murai. The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13. iScience. 2023. 26. 12. 108529-108529
Hidehiko Akashi, Nozomi Yachida, Haruka Ueda, Manako Yamaguchi, Kaoru Yamawaki, Ryo Tamura, Kazuaki Suda, Tatsuya Ishiguro, Sosuke Adachi, Yoshikazu Nagase, et al. SLFN11 is a BRCA independent biomarker for the response to platinum-based chemotherapy in high-grade serous ovarian cancer and clear cell ovarian carcinoma. Molecular cancer therapeutics. 2023
Junko Murai, Michele Ceribelli, Haiqing Fu, Christophe E. Redon, Ukhyun Jo, Yasuhisa Murai, Mirit I. Aladjem, Craig J. Thomas, Yves Pommier. Schlafen 11 (SLFN11) kills cancer cells undergoing unscheduled re-replication. Molecular Cancer Therapeutics. 2023. 22. 8. 985-995
Junko Murai, Yves Pommier. BRCAness, Homologous Recombination Deficiencies, and Synthetic Lethality. Cancer Research. 2023. 83. 8. 1173-1174

ｍore...

MISC (20)：

Takuma Kagami, Mihoko Yamade, Takahiro Suzuki, Takahiro Uotani, Shinya Tani, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, et al. THE FIRSR EVIDENCE FOR SLFN11 EXPRESSION AS AN INDEPENDENT PROGNOSTIC FACTOR FOR PATIENTS WITH ESOPHAGEAL CANCER AFTER CHEMORADIOTHERAPY. GASTROENTEROLOGY. 2020. 158. 6. S777-S778
Yves Pommier, Junko Murai. PARP trapping and Schlafen 11. MOLECULAR CANCER RESEARCH. 2017. 15
Junko Murai, Sai-Wen Tang, Yves Pommier. Schlafen 11 (SLFN11) blocks RNA synthesis upon replicative damage, a novel mechanism for killing cancer cells in response to DNA damaging agents. CANCER RESEARCH. 2016. 76
Junko Murai, Yves Pommier. The combination of the PARP inhibitor talazoparib (BMN 673) with the ATR inhibitor VE-821 overcomes the drug resistance of Schlafen 11-deficient cells. CANCER RESEARCH. 2015. 75
Y. Pommier, J. Murai. CLASSIFICATION OF PARP INHIBITORS BASED ON PARP TRAPPING AND CATALYTIC INHIBITION, AND RATIONALE FOR COMBINATIONS. ANNALS OF ONCOLOGY. 2015. 26. 8-8

ｍore...

Professional career (1)：

Work history (9)：

2022/05 - 現在 Ehime University Institute for Promotion of Science and Technology Proteo-Science Center
2018 - 現在慶應義塾大学・先端生命科学研究所/大学院政策メディア研究科・特任准教授
2015 - 2018 アメリカ国立衛生研究所研究員
2013 - 2014 京都大学大学院医学研究科メディカルイノベーションセンター特任助教
2012 - 2013 京都大学大学院医学研究科放射線遺伝学助教

Show all

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page